Références
1 Auperin A, Hill C. Épidémiologie des carcino- mes des voies aérodigestives supérieures. Cancer Radiother. 2005; 9: 1-7. 2 Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR et al. Marijuana use and increased risk of squamous cell car- cinoma of the head and neck. Cancer Epide- miol Biomarkers Prev. 1999; 8: 1071-8. 3 Shah JP. Cervical lymph node metastase – diagnostic, therapeutic and prognosis impli- cations. Oncology. 1990; 4: 61-9. 4 Pivot X, Schneider M, Demard F, editors. Car- cinomes épidermoïdes des voies aérodiges- tives supérieures : nouvelles stratégies diag- nostiques et thérapeutiques. Paris: Springler- Verlag; 2003. 5 Poissonnet G, Dassonville O, Pivot X, Demard F. Cancers du larynx et de l’hypopharynx: anato- mie, anatomopathologie, signes cliniques, TNM,
thérapeutique. Bull Cancer. 2000(Suppl 5): 27-38. 6 Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A et al, American Head and Neck Society. American Academy of Oto- laryngology Head and Neck Surgery. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otola- ryngology-Head and Neck Surgery. Arch Oto- laryngol Head Neck Surg. 2002; 128: 751-8. 7 Kolb F, Julieron M. Chirurgie réparatrice en can- cérologie ORL: principales méthodes et indica- tions. Cancer Radiother. 2005; 9: 16-30. 8 Lapeyre M, Marchesi V, Mege A, Aletti P, Graff P, Racadot S et al. Radiothérapie confor- mationelle avec modulation d’intensité des cancers des voies aérodigestives supérieures avec irradiation bilatérale du cou : résultats
préliminaires. Cancer Radiother. 2004; 8: 134-47. 9 Maingon P, Mammar V, Peignaux K, Truc G, Barillot I. Les contraintes aux organes à risque en radiothérapie par modulation d’in- tensité des cancers ORL. Cancer Radiother. 2004; 8: 234-47. 10 Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R et al. Simulta- neous radiochemotherapy versus radiothe- rapy alone in advanced head and neck can- cer: a randomized multicenter study. J Clin Oncol. 1998; 16: 1318-24. 11 Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993; 328: 184-94. 12 Pignon JP, Baujat J, Bourhis J. Apport des méta-analyses sur données individuelles au
1 Auperin A, Hill C. Épidémiologie des carcino- mes des voies aérodigestives supérieures. Cancer Radiother. 2005; 9: 1-7. 2 Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR et al. Marijuana use and increased risk of squamous cell car- cinoma of the head and neck. Cancer Epide- miol Biomarkers Prev. 1999; 8: 1071-8. 3 Shah JP. Cervical lymph node metastase – diagnostic, therapeutic and prognosis impli- cations. Oncology. 1990; 4: 61-9. 4 Pivot X, Schneider M, Demard F, editors. Car- cinomes épidermoïdes des voies aérodiges- tives supérieures : nouvelles stratégies diag- nostiques et thérapeutiques. Paris: Springler- Verlag; 2003. 5 Poissonnet G, Dassonville O, Pivot X, Demard F. Cancers du larynx et de l’hypopharynx: anato- mie, anatomopathologie, signes cliniques, TNM,
thérapeutique. Bull Cancer. 2000(Suppl 5): 27-38. 6 Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A et al, American Head and Neck Society. American Academy of Oto- laryngology Head and Neck Surgery. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otola- ryngology-Head and Neck Surgery. Arch Oto- laryngol Head Neck Surg. 2002; 128: 751-8. 7 Kolb F, Julieron M. Chirurgie réparatrice en can- cérologie ORL: principales méthodes et indica- tions. Cancer Radiother. 2005; 9: 16-30. 8 Lapeyre M, Marchesi V, Mege A, Aletti P, Graff P, Racadot S et al. Radiothérapie confor- mationelle avec modulation d’intensité des cancers des voies aérodigestives supérieures avec irradiation bilatérale du cou : résultats
préliminaires. Cancer Radiother. 2004; 8: 134-47. 9 Maingon P, Mammar V, Peignaux K, Truc G, Barillot I. Les contraintes aux organes à risque en radiothérapie par modulation d’in- tensité des cancers ORL. Cancer Radiother. 2004; 8: 234-47. 10 Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R et al. Simulta- neous radiochemotherapy versus radiothe- rapy alone in advanced head and neck can- cer: a randomized multicenter study. J Clin Oncol. 1998; 16: 1318-24. 11 Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993; 328: 184-94. 12 Pignon JP, Baujat J, Bourhis J. Apport des méta-analyses sur données individuelles au
traitement des cancers ORL. Cancer Radio- ther. 2005; 9: 31-6. 13 The department of Veteran Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685-90. 14 Janot F, Rhein B, Koka V. Préservation laryn- gée par chimiothérapie première. À propos de l’expérience de deux centres du GETTEC dans les cancers de l’endolarynx traités entre 1985 et 1995. Ann Otolaryngol Chir Cervico- fac. 2002; 119: 12-20. 15 Bernier J, Vermorken JB, Koch WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol. 2006; 24: 2629-35. 16 Hitt R, Grau J, Lopez-Pousa A, Berrocal A, García-Giron C, Belon J et al. Randomized phase II/III clinical trial of induction chemo- therapy (ICT) with either cisplatin/5-fluorou- racil (PF) or docetaxel/cisplatin/5-fluoroura- cil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol. 2006; 24(18 s): 283s (abst. 5515). 17 Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al. Concurrent che- motherapy and radiotherapy for organ pre- servation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-8. 18 Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al.
French multicenter phase III randomized study testing concurrent twice-a-day radio- therapy and cisplatin/5-fluorouracil chemo- therapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GOR- TEC). Int J Radiat Oncol Biol Phys. 2006; 64: 983-94. 19 Bernier J, Cooper JS, Pajak TF, Van Glabbeke M, Bouhris J, Forastière A et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postopera- tive radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27: 843-50. 20 Janot F, De Raucourt D, Castaing M, Bardet E, Dolivet G, Bensadoun R et al. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a rando- mized trial from the GETTEC and GORTEC groups. J Clin Oncol. 2006; 24(18 s): 282s (abst. 5508). 21 Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M et al. Expression of epidermal growth factor recep- tor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993; 11: 1873-8. 22 Magné N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O et al. The rela- tionship of epidermal growth factor receptor level to the prognosis of unresectable pharyn- geal cancer patients treated by chemo-radio- therapy. Eur J Cancer. 2001; 37: 2169-77. 23 Harari PM, Huang S. Head and neck cancer as a clinical model for molecular targeting of
therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001; 49: 427-33. 24 Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-78. 25 Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R et al. Phase II multi- center study of the antiepidermal growth factor receptor monoclonal antibody cetuxi- mab in combination with platinum-based chemotherapy in patients with platinum- refractory metastatic and/or recurrent squa- mous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 5568-77. 26 Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N et al. Phase II multicen- ter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 5578-87. 27 Rivera S, Keryer C, Busson P, Maingon P. Les carcinomas du nasopharynx: de la biologie à la clinique. Cancer Radiother. 2005; 9: 55-68. 28 Julieron M, Temam S. Récidives locorégiona- les des cancers ORL: place de la chirurgie. Bull Cancer. 2004; 91: 863-9. 29 Posner MR, Wirth LJ. Cetuximab and radiothe- rapy for head and neck cancer. N Engl J Med. 2006; 354: 634-6.
ليست هناك تعليقات:
إرسال تعليق